On December 5, 2022, Spectrum Pharmaceuticals, Inc. was sued for violations of the federal securities laws in the United States District Court for the Southern District of New York on behalf of investors who purchased the Company’s shares between December 6, 2021 and September 22, 2022, inclusive (the “Class Period”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.